Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden

OBJECTIVES: In Sweden, breast cancer (BC) represents 30% of newly diagnosed cancers and is the most common cancer in women. For hormone-dependent BC, endocrine therapies varying in efficacy and price are available. The aim of this study is to assess the cost effectiveness of fulvestrant 500 mg as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabale, Ugne, Ekman, Mattias, Thunström, Daniel, Telford, Claire, Livings, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711749/
https://www.ncbi.nlm.nih.gov/pubmed/29441507
http://dx.doi.org/10.1007/s41669-017-0031-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711749/
https://www.ncbi.nlm.nih.gov/pubmed/29441507
http://dx.doi.org/10.1007/s41669-017-0031-6

Ejemplares similares